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TLR9 signalling in microglia attenuates
seizure-induced aberrant neurogenesis in
the adult hippocampus
Taito Matsuda1, Naoya Murao1,2, Yuki Katano1,2, Berry Juliandi1,3, Jun Kohyama4, Shizuo Akira5,6,
Taro Kawai7 & Kinichi Nakashima1
Pathological conditions such as epilepsy cause misregulation of adult neural stem/progenitor
populations in the adult hippocampus in mice, and the resulting abnormal neurogenesis leads
to impairment in learning and memory. However, how animals cope with abnormal neuro-
genesis remains unknown. Here we show that microglia in the mouse hippocampus attenuate
convulsive seizure-mediated aberrant neurogenesis through the activation of Toll-like
receptor 9 (TLR9), an innate immune sensor known to recognize microbial DNA and trigger
inflammatory responses. We found that microglia sense self-DNA from degenerating neurons
following seizure, and secrete tumour necrosis factor-a, resulting in attenuation of aberrant
neurogenesis. Furthermore, TLR9 deficiency exacerbated seizure-induced cognitive decline
and recurrent seizure severity. Our findings thus suggest the existence of bidirectional
communication between the innate immune and nervous systems for the maintenance of
adult brain integrity.
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A
dult neural stem/progenitor cells (aNS/PCs) in the
subgranular zone (SGZ) of the adult hippocampal dentate
gyrus (DG) proliferate and give rise to new neurons
continuously throughout life to maintain proper brain functions1.
Although this homoeostatic neurogenesis is strictly controlled
under normal physiological conditions, misregulation of aNS/PCs
leads to aberrant neurogenesis and impairment of hippocampal-
dependent learning and memory under pathological conditions
such as stress, depression, ischaemia and epilepsy2. The aNS/PC
niche, a microenvironment comprising various components
including blood vessels, neurons, astrocytes and microglia, is
known to contribute to different aspects of neurogenesis under
both normal and pathological conditions2–7. However, how it
responds to pathological conditions to rectify any aberrant
behaviour of aNS/PCs is yet to be elucidated.
Microglia, the major immune cell type in the brain, remove
dying cells and cellular debris without inducing inflammation
under physiological conditions8. In response to pathological
insults such as infection or brain injury, activated microglia
accumulate in the injured site and secrete pro- and/or anti-
inflammatory cytokines9,10. In addition to these functions,
increasing evidence suggests that microglia play important roles
in aNS/PC regulation under physiological conditions11–13.
Toll-like receptors (TLRs) are innate immune receptors that
recognize pathogen- or damage-associated molecular patterns
(P/DAMPs)14–16, and provide an important machinery by which
microglia can sense both pathogen- and host-derived ligands and
consequently secrete pro- and/or anti-inflammatory cytokines.
While TLR2 and TLR4 have been implicated in adult
hippocampal neurogenesis under physiological conditions17, it
is completely unknown whether the nucleic acid-sensing TLR7
and TLR9 can also regulate neurogenesis. To elucidate the
functions of these TLRs is important, particularly in pathological
conditions, because nucleic acids released from endogenous
damaged cells could activate them, resulting in the misregulation
of aNS/PC behaviour.
We report here that the loss of TLR9 but not TLR7 reduced
seizure-mediated sustained microglial activation and tumour
necrosis factor-alpha (TNF-a) production in the hippocampus.
Pharmacological inhibition of microglial activation or TNF-a
production in wild-type (WT) mice exacerbated aberrant
neurogenesis to a similar extent to that observed in TLR9
knockout (KO) mice after seizure. Furthermore, conditioned
medium (CM) from hyperactivated hippocampal neurons
upregulated Tnf-a expression in primary cultures of WT but
not TLR9 KO microglia, and this effect was completely abolished
when the CM was pretreated with DNase. These results indicate
that microglia are activated through TLR9 signalling triggered by
self-DNA derived from seizure-induced degenerating neurons in
the hippocampus, leading to a sustained expression of TNF-a
which attenuates the induced aberrant neurogenesis.
Results
TLR9 deficiency aggravates aberrant neurogenesis. We found
that Iba1-positive microglia were in close proximity to about 80%
of aNS/PCs (positive both for green fluorescent protein (GFP)
expressed under the promoter of the NS/PC marker gene Sox2
and for the aNS/PC marker glial fibrillary acidic protein (GFAP))
in the SGZ of the hippocampus under both physiological and
pathological conditions (Supplementary Fig. 1a–c), implying that
niche-resident microglia activated in response to pathological
insults also affect the behaviour of aNS/PCs by producing
pro- and/or anti-inflammatory cytokines.
As a first step towards understanding the roles of TLR7 and
TLR9, we confirmed their expression in microglia and found that
they are much more highly expressed in these cells than in other
neural cell types including NSCs (Supplementary Fig. 1d). To
investigate the role of TLR7 and TLR9 in adult hippocampal
neurogenesis, we injected bromodeoxyuridine (BrdU) once a day
for 7 days into physiologically normal 8-week-old WT, TLR7-KO
and TLR9-KO mice to label proliferating aNS/PCs in the DG and
killed the mice 1 day after the final injection. We observed no
significant difference among these mice (Fig. 1a–c), since TLR
signalling is activated by P/DAMPs only under pathological
conditions15,16. Although we have previously reported that
convulsive seizure induces aberrant neurogenesis in the adult
DG18, how animals respond to this pathological condition
remains unknown. We thus sought to examine the effects of
TLR7 and TLR9 deficiency on the response to convulsive seizure
induction. To induce the seizure, we administered kainic acid
(KA), a potent glutamate analogue that triggers neuronal
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Figure 1 | TLR9 deficiency aggravates seizure-induced aberrant
neurogenesis. (a) Experimental timeline for assessing aNS/PC proliferation
in WT, TLR7-KO and TLR9-KO mice. (b) Representative images of the DG
and stained with BrdU (red) and Hoechst (blue) showed that KA-induced
proliferation of aNS/PCs in TLR9-KO mice was more extensive than in WT
mice. Scale bar, 50mm. (c) Quantification of total number of BrdU-positive
(BrdUþ ) cells in the DG with (filled bars) or without (open bars) KA
treatment. After seizure, the number of BrdUþ cells was higher in
TLR9-KO mice than in WTmice (n¼ 5 animals). (d,e) Representative
images of BrdU (red) and DCX (green) double-labelled (BrdUþDCXþ )
newly generated neurons in the SGZ (d) and the hilus (e) (n¼ 5 animals).
Scale bars, 50mm. White arrowheads indicate new neurons located
ectopically in the hilus. (f,g) Quantification of the number of BrdUþDCXþ
cells in c (SGZ, f) and e (hilus, g; n¼ 5 animals). *Po0.05, **Po0.01 and
***Po0.001 by analysis of variance with Tukey post-hoc tests.
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hyperactivation, intraperitoneally to WT, TLR7-KO and
TLR9-KO mice. KA-induced acute convulsive seizure is known
to trigger aberrant augmentation of neurogenesis in the DG and
the migration of newborn neurons to ectopic locations such as the
hilus, resulting in the impairment of hippocampus-dependent
memory3,18,19. Consistent with previous reports, we observed a
significant increase in the number of BrdU-positive cells within
the SGZ in all KA-treated mice (Fig. 1a–c). Interestingly, while
the number of BrdU-positive cells within the SGZ at 1 week after
KA administration did not differ between WT and TLR7-KO
mice, the number was higher in TLR9-KO mice (Fig. 1a–c).
In addition, an increased number of BrdU-retaining and
doublecortin (DCX, an immature neuron marker)-expressing
newly generated and immature neurons was observed in the DG,
including both the SGZ and the hilus, of TLR9-KO mice (Fig. 1d–
g), suggesting that the loss of TLR9 stimulates KA-induced
aberrant neurogenesis. We decided to focus on TLR9-KO mice in
the following experiments because neurogenesis in TLR7-KO
mice was indistinguishable from that in WT mice even in the
pathological condition.
We further traced the differentiation and survival of newly
generated cells in the DG at 3 weeks after the last BrdU injection
(Fig. 2a). The TLR9-KO mice showed a higher number of BrdU-
retaining cells in the DG than that in WT mice (Fig. 2b,d), and
the majority of BrdU-retaining cells had become positive for the
mature neuronal marker NeuN (Fig. 2b–e). However, the loss of
TLR9 had no effect on the proportion of NeuN-positive neurons
among BrdU-positive cells. Concordant with the increase in
BrdU-positive cells, the number of newly generated S100b- or
GFAP-positive astrocytes also increased in the DG of TLR9-KO
compared with WT mice (Fig. 2b–e), suggesting that aNS/PC
differentiation per se was not affected by the loss of TLR9 as
shown in Fig. 2f for neuronal differentiation as an example.
Furthermore, we measured the proportion of surviving total
BrdU-positive cells in WT and TLR9-KO mice. To calculate the
ratio of surviving cells after seizure, we divided the total number
of BrdU-positive cells at 3 weeks after the last BrdU injection by
that at 1 day after the last BrdU injection. We found no difference
in the survival ratio (Fig. 2g), indicating that TLR9 signalling does
not contribute to the survival of newborn cells in the DG. Taken
together, these results suggest that TLR9 deficiency aggravates
seizure-induced aberrant neurogenesis in the hippocampus by
promoting aNS/PC proliferation. In other words, these data
indicate that TLR9 signalling attenuates seizure-induced
abnormal proliferation of aNS/PCs to maintain homoeostatic
neurogenesis in the DG.
Activated microglia attenuates aberrant neurogenesis. Before
further analyzing TLR9 function, we determined whether TLR9 is
indeed expressed in microglia in the DG in vivo. As shown in
Supplementary Fig. 1e, Iba1-positive microglia clearly expressed
TLR9. We also examined whether i.p. KA injection compromises
the integrity of the blood–brain barrier (BBB) by using Evans blue
dye, because macrophages infiltrate the damaged brain in con-
ditions such as ischaemia through a disrupted BBB. However,
Evans blue dye leakage was not found in the brain, while the dye
was detected in other organs in both WT and TLR9-KO mice,
indicating that the BBB remains intact after KA injection in these
mice (Supplementary Fig. 1f). Although we cannot completely
exclude the possibility that macrophages infiltrate the brain after
seizure through the intact BBB, any such macrophage population
would be exceedingly small compared with the brain-resident
microglia. We therefore focused mainly on microglia as TLR9-
expressing cells in this study.
Since it has been shown that epileptic seizure induces
microglial activation in the hippocampus20, we evaluated the
microglial activation status in WT and TLR9-KO DG after seizure
by immunohistochemistry with an antibody against CD68, which
is upregulated in activated microglia (Supplementary Fig. 2a,b).
Many CD68-positive activated microglia were detected in WT
mice 7 days after seizure, whereas the activation was much lower
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Figure 2 | Loss of TLR9 increases newly generated mature neurons after seizure. (a) Experimental scheme for examining the number of newly generated
mature neurons. (b) Representative images of staining for NeuN (green) and BrdU (red) in the DG (n¼ 5 animals). Scale bar, 50mm. (c) Representative
images of BrdU (red) and S100b (green) staining in the DG of KA-administered WT and TLR9-KO mice. White arrowheads indicate BrdU and S100b
double-labelled newborn astrocytes. Scale bar, 50mm. (d,e) The DG of TLR9 KO mice exhibited increased numbers of BrdUþ cells (d) and newly
generated BrdUþNeuNþ mature neurons (e) (n¼ 5 animals). (f,g) Quantification of BrdUþ cells for assessing differentiation (f) and survival (g) of
newly generated cells in the DG (n¼ 5 animals). (d) *Po0.05 by Student’s t-test. (e) *Po0.05 and **Po0.01 by analysis of variance with Tukey post-hoc
tests.
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in TLR9-KO mice, indicating that sustained microglial activation
in the DG requires functional TLR9 (Fig. 3a). This result
prompted us to ask whether TLR9-mediated microglial activation
inhibits aNS/PC proliferation. To induce microglial activation, we
prepared primary cultured microglia (Supplementary Fig. 3a) and
stimulated them in vitro with the TLR9 ligand ODN1585.
Incubation of microglia with ODN1585 upregulated the
expression of two well-known targets of TLR signalling, Tnf-a
and Interferon (Ifn) b, in a dose-dependent manner
(Supplementary Fig. 3b). We then tested whether the CM of
microglia activated with ODN1585 affects aNS/PC proliferation,
and found that it decreased aNS/PC proliferation compared with
control CM without affecting cell survival (Fig. 3b–d). We also
performed experiments using different ligands (ODN2395 and
ODN1826) for TLR9, and found that CM from microglia
activated with these two ligands likewise inhibited aNS/PC
proliferation (Supplementary Fig. 4). These data indicate that
microglia activated through TLR9 inhibit aNS/PC proliferation
in vitro.
Minocycline, a semisynthetic tetracycline derivative, is known
to inhibit microglial activation in vivo21. To inhibit sustained
microglial activation after seizure, we injected minocycline
intraperitoneally into WT and TLR9-KO mice once daily
for 8 consecutive days. We confirmed that seizure-induced
microglial activation was inhibited by minocycline treatment
(Supplementary Fig. 2b). When we inhibited microglial activation
with minocycline in KA-administered WT mice, seizure-induced
aberrant neurogenesis was exacerbated, reaching a level similar to
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Figure 3 | Activated microglia attenuates aberrant neurogenesis. (a) Representative images of CD68þ (magenta) activated microglia in the DG of
TLR9 KO and WTmice with or without KA treatment (n¼4 animals). Scale bar, 50mm. (b) Experimental scheme for assessing aNS/PC proliferation in the
presence or absence of CM derived from ODN1585-stimulated microglia. (c) Representative images of EdU (red) and Hoechst (blue) staining of aNS/PCs
cultured with CM of ODN1585-treated (right) and untreated (left) microglia as a control (Ctrl) (n¼ 5 experiments). Scale bar, 50mm. (d) Quantification of
EdUþHoechstþ cells or an apoptotic cell marker active caspase3þHoechstþ cells. ODN1585-dependent microglial activation inhibits aNS/PCs without
affecting cell survival (n¼ 5 experiments). (e) Experimental scheme for assessing aNS/PC proliferation in minocycline-treated mice. (f) Representative
images of BrdUþ (red) DCXþ (green) newly generated neurons in the DG. Scale bar, 50mm. (g,h) Quantification of the number of BrdUþDCXþ cells in
the DG (g) and hilus (h) (n¼ 5 animals). Ectopic neurogenesis increased in minocycline-treated mice to a similar extent to that observed in TLR9 KO
mice (n¼ 5 animals). (d) *Po0.01 by Student’s t-test. (g,h) NS means not significant (P40.05). *Po0.05, **Po0.01 by analysis of variance with Tukey
post-hoc tests.
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that observed in TLR9-KO mice treated with KA alone
(Fig. 3e–h). Furthermore, there were no differences in the
number of BrdU- and DCX-positive cells (newly generated
neurons) between minocycline-treated or -untreated TLR9-KO
mice after seizure (Fig. 3f–h). Taken together, these results
suggest that activated microglia attenuate seizure-induced
neurogenesis through TLR9 signalling. Minocycline itself did
not affect neurogenesis under normal physiological conditions
(Supplementary Fig. 2c–e).
Microglia-derived TNF-a alleviates aberrant neurogenesis.
Recent studies have shown that various inflammation-related
molecules regulate adult neurogenesis in the DG22–24, leading us
to hypothesize that such molecules released from activated
microglia might attenuate aberrant neurogenesis induced by
seizure. To test this, we performed quantitative real-time PCR
(qRT–PCR) analysis. At one day after seizure induction,
expression of inflammatory cytokines, such as Il-1b, Il-6 and
Tnf-a, in both WT and TLR9-KO DG was upregulated compared
to KA-untreated controls (Fig. 4a and Supplementary Fig. 5).
Intriguingly, the higher expression level of Tnf-a and not other
mRNAs was sustained in KA-treated WT mice at 4 or 7 days after
seizure, yet the Tnf-a expression level in TLR9-KO mice reverted
to the control level by 4 days after seizure induction (Fig. 4a).
Given that TNF-a has previously been shown to suppress
neurogenesis in the DG23, we tested whether TNF-a inhibits aNS/
PC proliferation in vitro, and found that it did so in a dose-
dependent manner (Supplementary Fig. 6a,b). We also examined
whether IL-12 and IFN-g inhibit aNS/PC proliferation, because
their expression differed between WT and TLR9-KO mice at day
1 after seizure (Supplementary Fig. 5). However, we found no
difference in the number of EdU (a thymidine analogue)-positive
cells irrespective of IL-12 and IFN-g treatment, suggesting
that aNS/PC proliferation is unaffected by these cytokines
(Supplementary Fig. 6c–f). Therefore, we decided to focus on
TNF-a in subsequent experiments. To examine whether TLR9
signalling-mediated TNF-a production by microglia inhibits aNS/
PC proliferation, we pretreated CM samples from microglia
with a TNF-a-neutralizing antibody or immunoglobulin-G (IgG)
control, and added them to aNS/PC cultures (Fig. 4b). ODN1585-
untreated microglial CM pretreated with the TNF-a antibody did
not affect aNS/PC proliferation. In marked contrast, the anti-
proliferative effect of the CM from ODN1585-treated microglia
was abolished with the TNF-a antibody, indicating that TLR9
stimulation-induced TNF-a is the factor responsible for the
inhibition of aNS/PC proliferation (Fig. 4c,d).
Thalidomide is known as a BBB-permeable inhibitor of TNF-a
production25. To allow administered thalidomide enough time to
be fully effective in inhibiting Tnf-a expression by the time of KA
injection, we started the injection of thalidomide into WT mice 1
day before the KA injection, and continued once daily until 3
days after seizure; the mice were then killed 4 days after seizure.
As shown in Supplementary Fig. 6g,h, we found that thalidomide
treatment suppressed Tnf-a expression in the DG of WT mice 4
days after seizure. When we injected thalidomide into WT mice
once daily for 8 consecutive days, in accordance with our in vitro
experiments, suppression of TNF-a production aggravated
aberrant neurogenesis in vivo as observed in thalidomide-
untreated TLR9-KO mice after seizure (Fig. 4e–h).
Next, to understand more precisely the behaviour of aNS/PCs
in response to seizure, we examined aNS/PC proliferation at
earlier time points after KA administration in both WT and
TLR9-KO mice. After 1, 2, 3 and 4 days of KA administration, we
injected BrdU into these mice every 4 h (four times) and killed
them 12 h after the last BrdU injection (Supplementary Fig. 7a).
We found that the number of BrdU-positive cells which were
proliferating at day 4 after seizure induction in WT mice was
significantly higher than in untreated WT mice (Supplementary
Fig. 7b,d). In contrast, statistically different BrdU-positive cell
numbers between untreated and KA-treated mice were already
observed at day 2 in TLR9-KO mice (Supplementary Fig. 7b,d).
Moreover, these trends of increased BrdU-positive cell numbers
in WT and TLR9-KO mice were inversely correlated with the
degree of microglial activation and Tnf-a expression in these mice
(Supplementary Fig. 7c,e). As shown in Supplementary Fig. 7e, a
dramatic upregulation of Tnf-a expression in both WT and KO
mice was observed at day 1 after KA injection, probably
attributable to a direct effect of KA. By 2 days, Tnf-a expression
in KA-injected TLR9-KO mice had already reverted to a level
similar to that in the control, but was still high in KA-injected
WT mice, suggesting that the difference was attributable to TLR9
deficiency. To confirm the effectiveness of thalidomide on the
inhibition of Tnf-a expression, we then injected thalidomide into
WT mice 1 day before the difference in Tnf-a expression between
WT and TLR9 KO mice became apparent (day 2)
(Supplementary Fig. 8a). As shown in Supplementary Figs 7d
and 8c, BrdU-positive cells had not yet increased in response to
KA treatment at day 3 in WT mice, but we did observe an
increase of BrdU-positive cells in response to thalidomide
treatment (Supplementary Fig. 8b,c). We then examined whether
TNF-a reduces exacerbated neurogenesis in TLR9-KO mice after
seizure. We infused recombinant TNF-a protein into the DG of
TLR9-KO mice after seizure (Supplementary Fig. 9a) and found
that TNF-a indeed reduced the seizure-induced aberrant
neurogenesis in these mice (Supplementary Fig. 9b,c). Taken
together, these results indicate that TLR9 signal-regulated TNF-a
production by microglia is a critical process to withstand the
aberrant neurogenesis following seizure.
TLR9 signalling does not affect localization of new neurons.
Having shown that TLR9-dependent TNF-a production in
microglia attenuates seizure-induced aNS/PC proliferation and
ectopic generation of new neurons, we next asked whether TLR9
signalling affects the location of DCX-positive newly generated
neurons in the DG at 8 days after seizure. The loss of TLR9 had
no effect on the distribution of DCX-positive neurons, whereas
the number of DCX-positive neurons in each area examined was
increased in TLR9-KO mice after seizure compared with WT
mice (Supplementary Fig. 10a–c). Since microglia activation and
TNF-a production are important processes downstream of TLR9
signalling, minocycline and thalidomide treatment did not affect
the distribution but did increase the number of DCX-positive
cells, similar to TLR9 loss (Supplementary Fig. 10b). We also
examined the morphology of DCX-positive cells after seizure by
Sholl analysis and measurement of dendrite length. TLR9-KO
mice showed no significant differences in these analyses, although
KA itself affected the morphology of DCX-positive neurons
(Supplementary Fig. 11a–c). Thus, these data indicate that TLR9
deficiency aggravates seizure-induced aberrant neurogenesis in
the hippocampus by promoting aNS/PC proliferation.
Loss of TLR9 worsens seizure-induced behavioural impairments.
We have previously shown that seizure-induced aberrant neuro-
genesis impairs a hippocampal-dependent cognitive function18.
Since seizure-induced aberrant neurogenesis is exacerbated in
TLR9-KO mice, we examined whether KA-treated TLR9-KO
mice show further cognitive decline by subjecting KA-treated or
-untreated WT and TLR9-KO mice to a hippocampus-dependent
place recognition task (Fig. 5a). Administration of KA to WT
mice induced cognitive decline in agreement with our previous
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report18 (Fig. 5b). Moreover, the loss of TLR9 aggravated this
seizure-induced cognitive decline, although without KA
treatment WT and TLR9-KO mice showed no significant
difference in the test (Fig. 5b). When we inhibited microglial
activation in WT mice treated with KA using minocycline, the
level of impairment in these mice decreased to an extent similar
to that observed in TLR9-KO mice without treatment (Fig. 5b).
These data suggest that TLR9-mediated microglial activation
attenuates seizure-induced cognitive decline in WT mice.
A recent study has indicated that ectopically located new
neurons contribute to epileptogenesis26. This observation
prompted us to examine whether either TLR9 deficiency or
inhibition of microglia activation by minocycline affect the
severity of seizure induced by KA re-injection at 48 days after the
first KA injection (Fig. 5c). All mice showed no difference in
scores of seizure following the first KA injection (Fig. 5d,e).
Furthermore, the first administration of KA at low concentration
did not affect the scores in WT or TLR9-KO mice
(Supplementary Fig. 12a,b). However, when we re-injected KA
at low concentration to TLR9-KO mice 48 days after the first KA
injection, they developed more severe seizures compared with
WT mice (Fig. 5f,g). Minocycline treatment indeed aggravated
the symptoms in WT mice, albeit to a lesser extent than that
observed in TLR9 KO mice without minocycline, probably
because we ceased minocycline treatment at 7 days after the first
KA injection. During the 7 days after the first KA administration,
microglial activation was inhibited by minocycline, but resumed
after the cessation of this treatment. We therefore inferred that
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cultured with the indicated CM from microglia (n¼4 experiments). Scale bar, 50mm. (d) Quantification of EdUþ or active caspase3þ cells in c
(n¼4 experiments). (e) Experimental timeline for assessing aNS/PC proliferation in thalidomide (Thal)-treated mice. (f) Representative images of
BrdUþDCXþ newly generated immature neurons in the DG (n¼4 animals). Scale bar, 50mm. (g,h) Quantification of the number of BrdUþDCXþ cells
in f, in the DG (g) and in the hilus (h) (n¼4 animals). *Po0.05 and **Po0.01 by ANOVA with Tukey post-hoc tests.
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the inhibition of aberrant neurogenesis was less effective in
minocycline-treated WT mice than in untreated WT mice. Taken
together, these results suggest that TLR9 signalling attenuates
seizure-induced cognitive decline and recurrent seizure severity.
Degenerating neuron-derived DNA activates TLR9 signalling.
Finally, we addressed the possibility that an endogenous cell-
derived ligand activates TLR9 signalling in microglia after seizure.
Increasing evidence indicates that, in addition to detection of
PAMPs, TLRs contribute to the detection of damage to the CNS
by recognizing endogenous DAMPs released from dying or
degenerating cells15,16,27. As we have shown previously18, seizure
causes neuronal degeneration in the DG. We collected CM from
hippocampal neurons stimulated with KA, and cultured primary
microglia in its presence for 12 h (Fig. 6a). We found that the
Tnf-a expression level in primary WT microglia was increased by
the CM of KA-treated neurons. In contrast, the CM failed to
induce Tnf-a expression in TLR9-KO microglia (Fig. 6b). When
we pretreated the CM from KA-treated neurons with DNase, the
CM-induced elevation of Tnf-a expression in primary microglia
was abolished (Fig. 6c). These data suggest that DNA derived
from degenerating neurons activates TLR9 signalling in microglia
as an endogenous ligand. Moreover, we observed that the CM of
KA-treated neurons upregulated the expression of Tlr9 in
primary microglia, indicating the existence of a positive
feedback loop to enhance TLR9 signalling in microglia
(Fig. 6c). CM-induced Tlr9 expression was also severely
compromised by pretreatment with DNase.
The TLR9 signalling pathway is known to activate NF-kB,
which controls the expression of inflammatory cytokine genes28.
We examined whether CM from degenerating neurons induces
NF-kB activation in microglia via TLR9. When we cultured
microglia with CM derived from KA-stimulated hippocampal
neurons, p65 protein, a subunit of the NF-kB complex,
translocated into the nucleus, indicating that the CM can
indeed activate NF-kB in microglia (Supplementary Fig. 13a,b).
This activation was abolished by DNase or TLR9 inhibitor
(ODN2088) treatment (Supplementary Fig. 13a,b). These data
suggest that DNA derived from degenerating neurons evokes NF-
kB activation in microglia via TLR9.
Discussion
TLR9 was initially identified as a receptor that recognizes
microbial DNA29, but current research has shown that TLR9
can sense self-DNA as a DAMP30, and it appears to be involved
in numerous immune processes and autoimmune diseases14.
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However, it is unknown whether TLR9 senses self-DNA to
modulate CNS function in the absence of pathogen-derived DNA.
In the present study, we have suggested that TLR9 senses
self-DNA from degenerating hippocampal neurons to attenuate
seizure-induced aberrant neurogenesis, revealing a role for TLR9
in maintaining brain integrity. TLR7-KO mice, in contrast,
displayed no impaired phenotype, at least in neurogenesis.
Moreover, when we pretreated CM from KA-treated neurons
with RNase to deplete TLR7 ligand (RNA), the CM-induced
elevation of Tnf-a expression in primary microglia was not
abolished (Supplementary Fig. 14). These data suggest that self-
RNA from degenerating neurons does not function as a TLR7
ligand for the regulation of neurogenesis following seizure,
although TLR7 is known to recognize self-RNA and
microRNA31,32. The microRNA let-7, a highly abundant
regulator of gene expression in the CNS, activates TLR7 in
neurons and induces neurodegeneration31. Neuronal TLR7 is also
reported to sense self-RNA derived from neighbouring cells and
thus to impair axonal outgrowth of cortical neurons32. These
observations warrant further experimentation using TLR7-KO
and/or a double-KO with TLR9 to gain a better understanding of
how immune receptors recognize endogenous ligands from
neighbouring CNS cells and modulate brain functions.
We have shown that the activation of TLR9 signalling in
microglia induces TNF-a expression, resulting in the attenuation
of aberrant neurogenesis in the hippocampus. Consistent with
our findings, it has been reported that TNF receptor 1 (TNFR1)
expressed in aNS/PCs is a negative regulator for adult
hippocampal neurogenesis23. The loss of TNFR1 enhances
seizure-mediated aNS/PC proliferation and increases neuro-
genesis in the hippocampus. TNF-a is a key factor in the
immune response33, but it is unclear whether TNF-a has any
positive effects in the CNS since many studies have focused on its
roles as a negative effector in neurodegenerative disorders such as
Alzheimer’s disease34. Thus, our results unveil a positive aspect of
TNF-a function in the CNS for the maintenance of homoeostatic
neurogenesis.
The findings that microglia are in close proximity to aNS/PCs
(Supplementary Fig. 1a–c) and that inhibition of microglial
activation after seizure exacerbates aberrant neurogenesis
(Fig. 3e–h and Supplementary Fig. 2) highlight the importance
of microglia for the regulation of adult neurogenesis in the
aNS/PC niche. Consistent with these observations, several
previous studies have suggested that microglia inhibit adult
hippocampal neurogenesis12,13. However, it has also been
suggested that activated microglia promote neurogenesis by
secreting trypsinogen35. These contradictory assertions are
probably due to the contribution of different subtypes of
activated microglia to the regulation of neurogenesis. Microglia
can undergo different modes of polarized activation, which give
rise to potentially neurotoxic classic-M1 (characterized by the
release of pro-inflammatory factors) or potentially
neuroprotective alternative-M2 (characterized by the expression
of anti-inflammatory cytokines) subtypes10,36,37. In the CNS,
increasing evidence indicates that M1 microglia exacerbate
neurodegenerative disease through the production of pro-
inflammatory cytokines10. Minocycline is known as an inhibitor
of M1 microglial activation since it selectively inhibits M1
microglia-related gene expression21. Therefore, it is plausible
that M1 microglia release TNF-a and consequently attenuate
seizure-induced aberrant neurogenesis.
In this study, we have identified a novel, intrinsic mechanism
to attenuate aberrant neurogenesis that involves interactions
between TLR9-expressing immune cells and neural cells. We
show that TLR9 signalling activated by DNA from degenerating
neurons induces TNF-a production in microglia, resulting
in the inhibition of seizure-induced aberrant neurogenesis
(Supplementary Fig. 15). Thus, microglia in the aNS/PC niche
respond via TLR9 to the insult induced by seizure and ensure
homoeostatic neurogenesis. However, we suspect that our
proposed mechanism is one among many that contribute to
homoeostatic neurogenesis, because the aNS/PC niche is
composed of many types of cells and is vulnerable to a variety
of pathological stimuli. Future studies will reveal as-yet-unknown
mechanisms by which the niche reacts to these stimuli to ensure
the maintenance of brain homoeostasis. Boosting the functions of
these intrinsic mechanisms should offer therapeutic strategies for
diseases associated with abnormal neurogenesis, such as major
depression, ischaemia, Alzheimer’s disease and epilepsy.
Methods
Animals. All efforts were made to minimize animal suffering and to reduce the
number of animals used. Animals were housed on a 12/12-h light/dark cycle and
fed ad libitum. TLR7-KO and TLR9-KO mice were on a C57BL/6 background.
Sox2–GFP mice38 were a gift from F.H. Gage (Salk Institute, USA). Male 8-week-
old mice were used for this study. To induce seizure, the mice received i.p.
injections of KA (30mg kg 1; Enzo Life Sciences) dissolved in saline. Behaviour of
KA-treated mice was observed for 1 h after the injection and the seizure score was
recorded, according to previously described criteria39,40. Briefly, we used the
following seizure scale: no response (0), staring and reduced locomotion (1),
activation of extensors and rigidity (2), repetitive head and limb movements (3),
sustained rearing with clonus (4), loss of posture (5), and status epilepticus and
death (6). The scores did not differ between WT and TLR9 KO mice following KA
injection. To assess recurrent seizure severity, all mice were re-injected with KA
(10mg kg 1) at 48 days after the first KA injection (30mg kg 1).
The day after KA injection, BrdU (50mg kg 1; Sigma) dissolved in saline was
injected intraperitoneally into TLR7-KO, TLR9-KO and WT mice daily for 1 week
to monitor cell proliferation, differentiation and survival. These mice were killed 1
day or 21 days after the last injection of BrdU. The day before seizure induction,
minocycline (20mg kg 1; Sigma) dissolved in saline was injected intraperitoneally
into TLR9-KO and WT mice once daily for 8 consecutive days to inhibit microglial
activation. To inhibit seizure-induced TNF-a production, thalidomide
(250mg kg 1; Sigma) dissolved in 0.5% carboxymethylcellulose (Sigma) was
injected intraperitoneally into WT mice with the same time course as minocycline.
For the inhibition of TLR9-dependent TNF-a production, mice were treated with
thalidomide on day 1 after seizure and again the following day. To evaluate cell
proliferation at each day, we injected BrdU into mice every 4 h (four times) at 1, 2,
3 and 4 days after KA administration and killed the mice 12 h after the last BrdU
injection.
For the hippocampus-dependent recognition test, mice were transferred to the
testing room and acclimated for at least 1 h before habituation and testing. Each
mouse was habituated to the empty testing chamber (10min) for 3 days after being
handled for 3 days. The testing chamber was an opaque plastic chamber
(50 50 30 cm). Two identical objects were placed in the testing chamber, and
the mouse was allowed to explore the objects for 5min as the training phase and
then the mouse was taken out from the chamber. We then placed one of the two
objects in a new position where is a diagonal corners with the object placed in
familiar position (Fig. 5a). After a 5-min delay, the mouse was replaced in the
testing chamber again. The mouse was given 5min to explore the familiar and
displaced objects during the testing phase. Behaviour was recorded with a video
tracking system. Frequency of object interactions and time spent exploring each
object were recorded for subsequent data analysis. The testing chamber and used
objects were washed with 70% ethanol before the next mouse was tested. All mice
were subjected to behavioural testing at 6 weeks after seizure.
All mice were treated according to Fundamental Guidelines for Proper Conduct
of Animal Experiment and Related Activities in Academic Research Institutions
under the jurisdiction of the Ministry of Education, Culture, Sports, Science and
Technology of Japan.
Gene expression analysis. Total RNA was isolated from tissues and cells
using Sepasol-RNA I Super G (Nacalai Tesque) following the manufacturer’s
instructions. RNA quality of all samples was checked by spectrophotometer.
Reverse transcription reactions were carried out using the SuperScript VILO cDNA
Synthesis Kit (Life Technologies) according to the kit protocol. Primer sequences
used in this study can be found in Supplementary Table 1. qRT–PCR was
performed with SYBR green fluorescent dye using Step One Plus (Applied
Biosytems) and Mx3000 (Stratagene). GAPDH was used as an endogenous
control to normalize samples.
Immunohistochemistry. We performed immunohistochemistry as described
previously41. Briefly, male adult mouse brains were fixed in 4% paraformaldehyde
and 40-mm sections were cut with a cryostat. For staining with anti-BrdU antibody,
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brain sections were incubated for 15min with 2N HCl. The antibodies used were
anti-BrdU (1:1,000, AbD Serotec), anti-DCX (1:500, Abcam), anti-CD68 (1:500,
AbD Serotec), anti-Iba1 (1:500, Wako), anti-TLR9 (1:100, Imgenex), anti-GFAP
(1:2,000, Millipore), anti-S100b (1:500, Sigma), anti-GFP (1:500, Aves Labs) and
anti-NeuN (1:500, Millipore). Nuclei were stained using bisbenzimide H33258
fluorochrome trihydrochloride (Hoechst) (Nacalai Tesque).
Immunocytochemistry. Cells were fixed in 4% paraformaldehyde and processed
for immunostaining as described41. Cells were stained with one of the following
antibodies: anti-Iba1 (1:500, Abcam), anti-GFAP (1:500, Millipore), anti-active
caspase3 (1:500, R&D Systems), anti-BrdU (1:500, AbD Serotec), anti-p65 (1:500,
Abcam) and anti-CD11b (1:500, AbD Serotec). For anti-BrdU staining, fixed cells
were incubated with 2N HCl for 5min. EdU staining was performed using the
Click-iT EdU Alexa Fluor 555 Imaging Kit (Life Technologies) according to the
supplier’s protocol. Stained cells were visualized with a fluorescence microscope
(Zeiss Axiovert 200M, Zeiss).
Confocal imaging. Fluorescence images were obtained on a confocal laser
microscope (LSM710 and LSM780, Zeiss). For quantification of the percentage of
NS/PCs contacted by microglia, Z-series stacks of confocal images of GFP-
expressing Sox2-positive cells and Iba1-positive cells were taken. At least 50
randomly chosen GFP-positive cells in the DG per animal were analyzed. GFP-
positive cells whose cell bodies contacted microglial processes or cell bodies were
counted. For analysis of neuronal localization in the DG at 8 days after seizure,
Z-series stacks of confocal images of DCX-positive cells with Hoechst staining were
taken to determine the localization of DCX-positive cells. For analysis of dendritic
complexity and measurement of dendrite length in vivo, three-dimensional
reconstructions of the entire dendritic processes of individual DCX-positive
neurons were made from Z-series stacks of confocal images as previously
described42. Briefly, images were acquired at 0.5-mm intervals. The projection
images were traced and analyzed with ImageJ. At least 10 randomly chosen
DCX-positive cells in the DG per animal were analyzed. Sholl analysis for dendritic
complexity was performed by counting the number of dendrites that crossed a
series of concentric circles at 10-mm intervals from the cell soma.
Cell counts. BrdU-positive cells within the DG were counted using every 6th
section (240 mm apart). The number of counted cells was then multiplied by six to
provide an accurate estimation of the number of cells per DG. To calculate the total
number of marker-double-positive cells, at least 200 randomly chosen BrdU-
positive cells per animal were analyzed. Microscopic analysis yielded a ratio of
BrdU-positive cells colabelled with DCX, NeuN, GFAP and S100b. These ratios
were multiplied by the total number of BrdU-labelled cells to give estimates of the
total number of BrdU-positive immature or mature neurons and BrdU-positive
astrocytes. To estimate the ratio of surviving cells after seizure, the total number of
BrdU-positive cells at 3 weeks post injection of BrdU was divided by the total
number of BrdU-positive cells at day 1 post injection of BrdU.
Cell culture. We obtained primary microglia and astrocytes from mouse at
postnatal day 1 (P1) using a previously described protocol43, with some
modifications. To obtain mixed glial cell cultures, cortexes of WT and TLR9-KO
mice were carefully dissected after stripping of meninges. The tissue was digested
with papain (Sigma) at 37 C for 20min. After centrifugation (200g, 5min), the cell
pellet was resuspended in alpha-Minimum Essential Medium (MEM) with 5%
foetal bovine serum (FBS) and 0.6% glucose, and the suspension was passed
through a 40-mm Cell Strainer (BD Falcon). After centrifugation (200g, 5min), the
cell pellet was resuspended in DMEM containing 10% FBS and a low concentration
of GM-SCF (0.1 ngml 1; PeproTech) to enhance microglial proliferation. These
mixed glial cells were plated in poly-L-lysine-coated T75 tissue culture flasks. The
medium was renewed every 2–3 days. Ten days after plating, microglia and
oligodendrocyte precursor cells (OPCs) were detached from astrocyte monolayer
sheets by shaking, collected and plated onto uncoated 35-mm culture dishes to
remove OPCs. After a 30-min incubation, the medium was removed by suction and
DMEM containing 10% FBS without GM-SCF was added to the dish. Two days
after plating, primary microglia from WT and TLR9-KO mice were used for assays.
After the shake-off procedure for the isolation of microglia, Trypsin EDTA
solution (Nacalai Tesque) was added to the flask to obtain the remaining astrocytes,
which were transferred to a 35-mm culture dish and maintained in DMEM
containing 10% FBS. Two days after plating, the astrocytes were used for assays.
Neuronal cultures were prepared from P1 mouse hippocampus according to a
previously described protocol44, with some modification. In brief, the hippocampus
was digested with papain at 37 C for 20min and triturated with a 1-ml pipette.
MEM with 5% FBS and 0.6% glucose was added and the mixture was plated onto a
poly-L-lysine-coated 35-mm culture dish. After 3 h, the medium was replaced with
maintenance medium (Neurobasal Medium (Gibco) supplemented with B27
(Gibco)) containing cytosine b-D-arabinofuranoside (5mM; Sigma) to eliminate
proliferating cells. To avoid neuronal cell death by a complete medium change, half
of the medium was replaced every 3 days with fresh maintenance medium. After 12
days, the neurons were used for assays.
To obtain NS/PCs, P1 mouse hippocampus was dissected and triturated in
Hank’s balanced salt solution. After centrifugation (200g, 5min), the cell pellet was
resuspended in N2-supplemented DMEM/F-12 medium containing 10 ngml 1
bFGF (PeproTech), plated on a poly-L-ornithine/fibronectin-coated dish and
incubated for 4 days. The cells were passaged by replating on an ornithine/
fibronectin-coated dish in N2 medium with 10 ngml 1 each of bFGF and EGF
(PeproTech)45. NS/PCs that had been passaged 10 times were used for qRT–PCR
analysis.
aNS/PC proliferation assay. For the in vitro aNS/PC proliferation assay, we used
aNS/PCs derived from rat hippocampus as previously described46. To determine
the effect of candidate cytokines, aNS/PCs were cultured in the presence of
murine TNF-a, murine IL-12 and murine IFN-g (all PeproTech) for 3 days.
N2-supplemented DMEM/F-12 medium containing bFGF (5 ngml 1) was
used as culture medium in this assay.
Cell supernatant collection. To analyze the role of microglia in aNS/PC
proliferation, microglia obtained from WT mice were cultured in the presence or
absence of ODN1585 (0.3 mM; InvivoGen), ODN1826 (1mM; InvivoGen) and
ODN2395 (1mM; InvivoGen) for 3 h and washed with PBS. DMEM containing
10% FBS was added to microglial cultures and incubated for 21 h. CM was then
collected. aNS/PCs were cultured with 30% microglial CM for 3 days. For the
aNS/PC proliferation assay, either BrdU or EdU was added (to 10 mM) to the
culture medium 30min before fixation. For TNF-a neutralization experiments,
microglial CM was supplemented with 10 mgml 1 anti- mouse TNF-a (R&D
Systems) or 10 mgml 1 normal goat IgG as a control and incubated at 37 C for
1 h before it was added to the aNS/PC culture.
To confirm microglial activation by endogenous ligand derived from neurons,
neurons were cultured in the presence or absence of KA (100 mM) for 1 h and
washed with Neurobasal Medium. To avoid neuronal cell death caused by a
complete medium change, we then added a 1:1 mixture of fresh and used
maintenance medium, which is CM from cultured neurons without any
stimulation. After 24 h, we collected the CM. Primary microglia were treated with
30% neuronal CM. To determine whether endogenous ligand derived from
degenerating neurons was DNA, CM from KA-treated neurons was pre-incubated
with 50mgml 1 of DNase (Roche) at 37 C for 1 h. For NF-kB activation analysis,
primary microglia were treated with 30% CM from unstimulated or KA-stimulated
neurons. Microglia cultured with the CM were stained with anti-p65 antibody. The
TLR9 agonist ODN1826 was added to primary microglia as a positive control to
induce the translocation of p65 protein into the nucleus. To determine whether
NF-kB is activated by TLR9 signalling, microglia were pretreated with TLR9
antagonist (ODN2088) for 1 h before addition of CM and the translocation of p65
into the nucleus was examined.
Osmotic pump infusion. In murine TNF-a-infusion experiments, KA-treated
TLR9-KO mice were infused with recombinant TNF-a (120 ng per day;
PeproTech) into the right ventricle by osmotic minipumps (Alzet) for 5 days with
the following coordinates: posterior¼ 0.34mm from Bregma, lateral¼ 1mm,
ventral¼ 3mm, as previously described47.
Evans blue injection. A 2% solution of Evans blue dye (Sigma) in 0.9% NaCl was
intravenously injected into WT and TLR9-KO mice in a dose of 2ml kg 1 at
3 days after seizure. All mice were killed 3 h after the Evans blue injection.
Statistical analysis. Statistical comparisons were made by Student’s t-test (for
two-group comparisons) and analysis of variance (for multiple group comparisons)
with Tukey post-hoc tests. Data represent meanþ s.e.m.
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